Trial · NCT03140969
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes | QR-110 Low Dose | 6 | Participants | ||
| Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes | QR-110 Mid Dose | 5 | Participants | ||
| Frequency and Severity of Non-ocular Adverse Events | QR-110 Low Dose | 6 | Participants | ||
| Frequency and Severity of Non-ocular Adverse Events | QR-110 Mid Dose | 5 | Participants | ||
| Change in Best-corrected Visual Acuity (BCVA) | QR-110 Low Dose | Baseline (Absolute Values) | 2.597 | Standard Deviation 1.2738 | logMAR |
| Change in Best-corrected Visual Acuity (BCVA) | QR-110 Mid Dose | Baseline (Absolute Values) | 2.990 | Standard Deviation 1.4153 | logMAR |
| Change in Best-corrected Visual Acuity (BCVA) | QR-110 Low Dose | Changes from Baseline - Visit 8 (M3) | -0.813 | Standard Deviation 1.0073 | logMAR |
| Change in Best-corrected Visual Acuity (BCVA) | QR-110 Mid Dose | Changes from Baseline - Visit 8 (M3) | -0.126 | Standard Deviation 0.2165 | logMAR |
| Change in Best-corrected Visual Acuity (BCVA) | QR-110 Low Dose | Changes from Baseline - Visit 13 (M6) | -0.903 | Standard Deviation 1.0189 | logMAR |
| Change in Best-corrected Visual Acuity (BCVA) | QR-110 Mid Dose | Changes from Baseline - Visit 13 (M6) | -0.122 | Standard Deviation 0.1801 | logMAR |
| Change in Best-corrected Visual Acuity (BCVA) | QR-110 Low Dose | Changes from Baseline - Visit 17 (M9) | -0.923 | Standard Deviation 1.0417 | logMAR |
| Change in Best-corrected Visual Acuity (BCVA) | QR-110 Mid Dose | Changes from Baseline - Visit 17 (M9) | 0.386 | Standard Deviation 0.9610 | logMAR |
| Change in Best-corrected Visual Acuity (BCVA) | QR-110 Low Dose | Changes from Baseline - Visit 21 (M12) | -0.927 | Standard Deviation 1.0492 | logMAR |
| Change in Best-corrected Visual Acuity (BCVA) | QR-110 Mid Dose | Changes from Baseline - Visit 21 (M12) | -0.106 | Standard Deviation 0.1545 | logMAR |
| Change in Full-field Stimulus Test (FST) | QR-110 Low Dose | -0.7 | Standard Deviation 0.33 | log cd/m2 | |
| Change in Full-field Stimulus Test (FST) | QR-110 Mid Dose | -1.2 | Standard Deviation 0.82 | log cd/m2 | |
| Change in Full-field Stimulus Test (FST) | QR-110 Low Dose | -0.6 | Standard Deviation 0.76 | log cd/m2 | |
| Change in Full-field Stimulus Test (FST) | QR-110 Mid Dose | -0.9 | Standard Deviation 0.82 | log cd/m2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03140969/results